INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (350, 12, 'Nivolumab', '<b>Nivolumab</b>', '<b>Nivolumab</b> 3 mg/kg IV<br> Repeat Every 14 Days<br> Until disease progression or Unacceptable toxicity', 'Minimal', 'Rizvi, NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. $Lancet Oncol. 2015 Mar;16(3):257-65.$', '','Opdivo');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (351, 12, 'Docetaxel/Ramucirumab', '<b>Docetaxel/Ramucirumab</b>', '<b>Docetaxel</b>75 mg/m <sup>2</sup>IV<br> Repeat Every 21 Days<br> <b>Ramucirumab</b> 10 mg/kg IV  <br> Repeat Every 21 days<br>Until disease pogression or Unacceptable toxicity', 'Moderate', 'Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. $Lancet. 2014 Aug 23;384(9944):665-73.$', '','Docetaxel:Taxotere<br> Ramicurimab:Cyramza');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (352, 12, 'Alectinib', '<b>Alectinib</b>', '<b>Alectinib</b> 600 mg PO BID<br>', 'Minimal', 'Ou SI, Ahn Js, Petris LD, et al. Alectinib in Crizotinib refractory ALK-rearranged non-small cell lung cancer: A phase II global study. $ J Clin Oncol. 2015 Nov 23. pii: JCO639443. $', '','Alecensa');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (353, 12, 'Ceritinib', '<b>Ceritinib</b>', '<b>Ceritinib</b> 750 mg  PO daily<br> ', 'Minimal', 'Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. $N Engl J Med. 2014 Mar 27;370(13):1189-97.$', '','Zykadia');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (354, 12, 'Necitumumab/Gemcitabine/Cisplatin', '<b>Necitumumab<br>Gemcitabine<br>Cisplatin</b>', '<b>Necitumumab</b> 800 mg IV Day 1 and 8<br><b>Gemcitabine</b>1250 mg/m <sup>2</sup> IV<br><b>Cisplatin</b> 75 mg/m<sup>2</sup>IV<br>Repeat every 21 days<br>Continue Necitumumab until disease progression or intolerable toxicity', 'Severe', 'Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first line therapy in patients with stage IV sqaumous non-small cell lung cancer (SQUIRE): an open label, randomised, controlled phase 3 trial. $Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.$', '','Necitumumab:Portrazza<br> Gemcitabine:Gemzar<br> Cisplatin<br>Various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (355, 12, 'Osimertinib', '<b>Osimertinib</b>', '<b>Osimertinib</b> 80 mg  PO daily<br> ', 'Minimal', 'Mitsudomi T, Tsai C, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced non-small cell lung carcinoma:AURA 2 phase II study. Presented at 16th world conference on lung cancer:September 6-9; Denverm CO. Abstract 1406. $', '','Tagrisso');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (356, 12, 'Pembrolizumab', '<b>Pembrolizumab</b>', '<b>Pembrolizumab</b> 2 mg /kg IV<br> Every 21 days', 'Minimal', 'Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. $N Engl J Med 2015; 372:2018-2028.$', '','Keytruda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (357, 31, 'ibrutinib', '<b>ibrutinib</b>', '<b>Ibrutinib</b> 560 mg PO daily (for Mantle Cell Lymphoma)<br>420 mg PO daily for Waldenstrom''s <br> ', 'Minimal', 'Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.$N Engl J Med. 2013 Aug 8;369(6):507-16.$', '','Imbruvica');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (358, 12, 'Afatinib', '<b>Afatinib</b>', '<b>Afatinib</b> 40 mg PO daily', 'Minimal', 'Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.$J Clin Oncol. 2013 Sep 20;31(27):3327-34.$', '','Gilotrif');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (359, 12, 'Gefitinib', '<b>Gefitinib</b>', '<b>Gefitinib</b> 250 mg PO daily', 'Minimal', 'Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. $N Engl J Med. 2010 Jun 24;362(25):2380-8. ', '','Iressa');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (360, 31, 'Belinostat', '<b>Belinostat</b>', '<b>Belinostat</b> 1000 mg/m<sup>2</sup>  days 1-5, <br> Repeat every 21 days', 'Minimal', 'Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.$Br J Haematol. 2015 Mar;168(6):811-9.$', '','Beleodaq');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (361, 30, 'Brentuximab Vedotin', '<b>Brentuximab Vedotin</b>', '<b>Bretuximab Vedotin</b> 1.8 mg/ kg<br> Repeat every 21 days', 'Minimal', 'Moscowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin''s lymphoma at risk of relapse or progression: a randomised, double-blind, placebo-controlled, phase 3 trial. $Lancet. 2015 May 9;385(9980):1853-62. $', '','Adcetris');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (362, 34, 'Idelalisib/Rituximab', '<b>Idelalisib/Rituximab</b>', '<b>Idelalisib</b> 150 mg  po BID <br> Rituximab 375 mg/m<sup>2</sup> Repeat every 21 days', 'Minimal', 'Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. $N Engl J Med. 2014 Mar 13;370(11):997-1007.$', '','Idelalisib:Zydelig<br> Rituximab:Rituxan');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (363, 34, 'Ibrutinib', '<b>Ibrutinib</b>', '<b>Ibrutinib</b> 420 mg PO daily', 'Minimal', 'Byrd JC, Brown JR, O''brien S .Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.$N Engl J Med. 2014 Jul 17;371(3):213-23.$', '','Imbruvica');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (364, 34, 'Ofatumumab/Chlorambucil', '<b>Ofatumumab<br>Chlorambucil</b>', '<b>Ofatumumab</b> 300mg IV on Day 1 and 1000 mg on day 8, Cycle 1. Subsequent cycles 1000 mg IV on Day 1 only <br><b>Chlorambucil</b> PO 10 mg/m<sup>2</sup>, day 1 to 7. Repeat every 28 days', 'Minimal', 'Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukemia  (Complimet1 (: A rondomised, multicentre, open-label phase 3 trial. $Lancet. 2015 May 9;385(9980):1873-83. $', '','Ofatumumab:Arzerra<br> Chlorambucil:Various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (365, 32, 'Blinatumomab', '<b>Blinatumomab</b>', '<b>Blinatumomab</b> 9  mcg/day on days 1-7, 28 mcg/day on days 8-28 of the first 42 day cycle<br>28 mcg/day on day1-28 in later cycles', 'Minimal', '', '','Blincyto');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (366, 37, 'Ixazomib/Lenolidamide/Dexamethasone', '<b>Ixazomib/Lenolidamide/Dexamethasone</b>', '<b>Ixazomib</b> 4 mg PO  on days 1,8,15<br> <br> <b>Lenalidomide</b> 25mg on day 1 thru 21<br> <b>Dexamethasone</b> 40 mg PO, days 1,8,15,22<br> Repeat every 28 days', 'Moderate', 'Kumar SK, Berdeja JG, Niesvizky, R. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously unreated multiple myeloma . $Lancet Oncol. 2014 Dec;15(13):1503-12. $', '','Ixazomib:Ninlaro<br> Lenalidamide:Revlimid<br> Dexamethasone:Decadron');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (367, 37, 'Daratumumab', '<b>Daratumumab</b>', '<b>Daratumumab</b> 16 mg/kg  every 7 days x 8 weeks <br> every 14 days x 16 weeks<br>then every 4 weeks until disease progression', 'Minimal ', 'Lokhorst HM, Plesner T, Laubach JP, et al Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. $N Engl J Med. 2015 Sep 24;373(13):1207-19.$', '','Darzalex');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (368, 22, 'Nivolumab', '<b>Nivolumab</b>', '<b>Nivolumab</b> 3 mg/kg IV<br> Repeat Every 14 Days<br> Until disease progression or Unacceptable toxicity', 'Minimal', 'Motzer RJ, Escudier B, McDermott DF, et al.  Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma. $N Engl J Med. 2015 Nov 5;373(19):1803-13. $', '','Opdivo');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (369, 49, 'Axitinib', '<b>Axitinib</b>', '<b>Axitinib <br>5 mg po BID', 'Minimal', 'Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus Sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. $Lancet Oncol. 2013 May;14(6):552-62. $', '','Inlyta');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (370, 50, 'Vemurafinib', '<b>Vemurafinib</b>', '<b>Vemurafenib</b> 960 mg po BID', 'Minimal', 'Sosman JA, Kim KB, Schuchter L, Survival in BRAF V600-Mutant advanced Melanoma treated with Vemurafenib. $N Engl J Med. 2012 Feb 23; 366(8): 707–714 .$', '','Zelboraf');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (371, 50, 'Ipilumimab', '<b>Ipilumimab</b>', '<b>Ipilumimab</b>  IV 3 mg/kg  every 3 weks upto 4 doses', 'Minimal', 'Hodi FS, O''Day SJ, McDermott DF, et al. Improved survival with Ipilumimab in patients with Metastatic Melanoma. $N Engl J Med 2010; 363:711-723. $', '','Yervoy');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (372, 50, 'Ipilumimab/Nivolumab', '<b>Ipilumimab/Nivolumab</b>', '<b>Ipilumimab</b> 3mg/kg  IV <br> Nivolumab </b> 1 mg/kg IV<br> every 3 weeks  x 4 cycles <br> followed by Nivolumab 3 mg/kg  every 3 weeks until disease progression on unaccceptable toxicity', 'Minimal', 'Postow, MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilumimab versus Ipilumimab in untreated melanoma. $N Engl J Med. 2015 May 21;372(21):2006-17. $', '','Ipilumimab:Yeroy<br> Nivolumab:Opdivo');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (373, 50, 'Dabrafenib/Trametinib', '<b>Dabrafenib/Trametinib</b>', '<bDabrafenibt</b> 150 mg PO  BID <br> Trametinib</b>2 mg once daily ', 'Minimal', 'Robert c, Karaszewska B, Schachter J, et al. Improved overall Survival in Melanoma with combines Dabrafenib and Trametinib. $ N Engl J Med. 2015 Jan 1;372(1):30-9.$', '','Dabrafenib:Tafilnar<br> Trametinib:Mekinist');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (374, 50, 'Cobimetinib/Vemurafenib', '<b>Cobimetinib/Vemurafenib</b>', '<b>Cobimetinib</b> 60 mg once daily<br>Vemurafenib</b>960 mg twice a day from day1-21, on a 28 day cycle ', 'Minimal', 'Larkin J, Ascierto PA, Dreno B. Combined Vemurafenib and Cobimetinib in BRAF-mutated Melanoma. $N Engl J Med. 2014 Nov 13;371(20):1867-76. $', '','Cotellic');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (375, 50, 'Pembrolizumab', '<b>Pembrolizumab</b>', '<b>Pembrolizumab</b> 2 mg /kg IV<br> Every 21 days', 'Minimal', 'Robert C, Schachter J, Long GV, et al.  Pembrolizumab versus Ipilumimab in Advanced Melanoma. $N Engl J Med 2015; 372:2521-2532. $', '','Keytruda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (376, 37, 'Elotuzumab/Lenalidomide/Dexamethasone', '<b>Elotuzumab<br>Lenalidomide<br>Dexamethasone</b>', '<b>Elotuzumab</b> 10 mg/Kg IV  Weekly x2 and then Every 2 weeks<br> <b>Lenalidomide</b> 25 mg po daily  from day 1-21 (3 weeks)<br> <b>Dexamethasone </b> 8 mg IV prior to Elotuzumab infusion and then 28 mg orally, In weeks without Elotuzumab  40 mg PO every week', 'Minimal', 'Lonial S, Dimopoulous M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma .$ N Engl J Med. 2015 Aug 13;373(7):621-31. $', '','Elotuzumab:Empliciti<br> Lenalidomide:Revlimid<br> Dexamethasone:Decadron, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (377, 4, 'Trifluridine/Tipiracil', '<b>Trifluridine/Tipiracil</b>', '<b>Trifluridine/Tipiracil</b>  35  mg/m<sup>2</sup>  PO twice daily days 1 through 5 and 8 through 12<br> Repeat every 28 days', 'Minimal', 'Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer.$ N Engl J Med. 2015 May 14;372(20):1909-19..$Lancet Oncol. 2014 Oct;15(11):1195-206. $', '','Lonsurf');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (378, 4, 'Ramicirumab/FOLFIRI', '<b>Ramicirumab/FOLFIRI</b>', '<b>Ramicirumab</b> 8 mg/kg IV <br> <b>Irinotecan  </b> 180 mg/m<sup>2</sup>  over 90 minutes <br> <b>Leucovorin</b> Calcium 400 mg/m<sup>2</sup> IV<br>FOLLOWED BY<br><b>Fluorouracil</b> 400 mg<sup>2</sup> IV<br> <b>Fluorouracil</b> 2,400 mg<sup>2</sup>  CIVI over 46 hours<br>Repeat every 14 days', 'Moderate', 'Tabernero J, Yoshino T, Cohn Al, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. $ Lancet Oncol. 2015 May;16(5):499-508. $', '','Ramucirumab:Cyramza');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (379, 6, 'Ramucirumab/Paclitaxel', '<b>Ramucirumab/Paclitaxel</b>', '<b>Ramucirumab</b> 8 mg/kg IV  on days 1 and 15<br>  <b>Paclitaxel</b> 80 mg/m<sup>2</sup>  IV on days 1, 8, 15<br>Repeat every 28 days', 'Moderate', 'Wilke H, Muro K, Van Custem E, et al. Ramucirumab plus paclitaxel versus placebo plus palcitaxel in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma I RAINBOW): a double-blind, randomised phase 3 trial. $Lancet Oncol. 2014 Oct;15(11):1224-35. $', '','Ramucirumab:Cyramza<br> Paclitaxel:Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (380, 6, 'Ramucirumab', '<b>Ramucirumab</b>', '<b>Ramucirumab</b> 8 mg/kg IV  every 2 weeks<br>  ', 'Minimal', 'Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. $ Lancet. 2014 Jan 4;383(9911):31-9. $', '','Cyramza');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (381, 11, 'Irinotecan liposome/Fluorouracil/Leucovorin', '<b>Irinotecan liposome<br>Fluorouracil<br>Leucovorin</b>', '<b>Irinotecan liposome</b> 70 mg/m<sup>2</sup> IV <br> <b>Fluorouracil</b> 2400 mg/m<sup>2</sup>  IV over 46 hours<br> <b>Leucovorin</b> 400mg/m<sup>2</sup> IV <br> Repeat every 14 days', 'Moderate', 'Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open label, phase 3 trial. $ Lancet. 2015 Nov 20. pii: S0140-6736(15)00986-1. $', '','Liposomal Irinotecan:Onivyde');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (382, 11, 'nab-Paclitaxel/Gemcitabine', '<b>nab-Paclitaxel/Gemcitabine</b>', '<b>nab-Paclitaxel</b> 125 mg/m<sup>2</sup> IV<br> <br> <b>Gemcitabine</b>  1000 mg/m<sup>2</sup>  days 1, 8, 15<br> Repeat every 28 days', 'Moderate', 'Von Hoff DD, Ervin T, Arena FP, et al. Incrased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. $ N Engl J Med. 2013 Oct 31;369(18):1691-703. $', '','nab-paclitaxel:Abraxane<br> Gemcitabine:Gemzar');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (383, 15, 'Pablociclib/Letrozole', '<b>Pablociclib/Letrozole</b>', '<b>Pablociclib</b>125 mg PO  on days 1 through 21<br>  <b>Letrozole</b> 2.5 mg PO daily<br> Repeat every 28 days', 'Minimal', 'Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/Trio-18): a randomised phase 2 study. $Lancet Oncol. 2015 Jan;16(1):25-35. $', '','Pablociclib:Ibrance<br> Letrozole:Femara');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (384, 15, 'Everolimus/Exemestane', '<b>Everolimus/Exemestane</b>', '<b>Everolimus</b> 10 mg PO daily <br>  <b>Exemestane</b> 25 mg PO daily', 'Minimal', 'Beck JT, Hortobogyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR +, HER2 - advanced breast cancer in BOLERO-2. $ Breast Cancer Res Treat. 2014 Feb;143(3):459-67. $', '','Everolimus:Afinitor<br> Exemestane:Aromasin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (385, 16, 'Pertuzumab/Trastuzumab/Docetaxel', '<b>Pertuzumab/Trastuzumab/Docetaxel</b>', '<b>Pertuzuamb</b>840  mg IV loading dose followed by 420 mg <br><b>Docetaxel</b> 75 mg/m<sup>2</sup> IV<br> <b>Trastuzumab</b> 8 mg/kg loading dose followed by 6 mg/kg<br> Repeat every 21 days', 'Moderate', 'Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. $ N Engl J Med. 2012 Jan 12;366(2):109-19. S', '','Pertuzumab:Perjeta<br> Trastuzumab:Herceptin<br> Docetaxel:Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (386, 16, 'ado-trastuzumab', '<b>ado-trastuzumab</b>', '<b>ado-trastuzumab</b>3.6 mg/kg IV every 21 days', 'Minimal', 'Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. $ N Engl J Med. 2012 Nov 8;367(19):1783-91. $', '','Kadcyla');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (387, 35, 'Bosutinib', '<b>Bosutinib</b>', '<b>Bosutinib</b> 500 mg po daily', 'Minimal', 'Cortes JE, et al. Bosutinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.$ J Clin Oncol.2012  October 30;(28):3486-3492. $', '', 'Bosulif');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (388, 35, 'Ponatinib', '<b>Ponatinib</b>', '<b>Ponatinib</b> 45 mg po daily', 'Minimal', 'Cortes JE, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemia.$N Engl J Med.2013 Nov 7;369(19):1783-96. $', '', 'Iclusig');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (389, 35, 'Omacetaxine', '<b>Omacetaxine</b>', '<b>Omacetaxine</b> 1.25 mg<sup>2</sup>  SQ twice daily for 14 days on a 28 day cycle (Induction)<br>1.25 mg<sup>2</sup>  SQ twice daily for 7 days on a 28 day cycle (maintenance)', 'Minimal', 'Cortes JE, et al. phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phaseCML with T315I mutation.$Blood.2012 Sep;120(13):2573-2580.$', '', 'Synribo');
